Exhibit
Number
Description of Document
10.31
Research, Development and LicenseAgreement between the Registrant and Glaxo Group
Limited datedMarch 30, 2010. Portions of this exhibit have been omitted and separately
filed with the SECwith a request for confidential treatment. (25)
10.32
First Amendment to LoanAgreement between the Registrant and RBSAsset Finance, Inc.
dated September 30, 2009. (24)
10.33
LeaseAgreement dated September 6, 2005 between the Registrant and BMR-2282 Faraday
Avenue LLC. (18)
10.34
Stock PurchaseAgreement dated December 17, 2008, among the Registrant, Ibis
Biosciences, Inc. andAbbott Molecular Inc. Portions of this exhibit have been omitted and
separately filed with the SECwith a request for confidential treatment. (23)
10.35
ResearchAgreement datedAugust 10, 2011 between the Registrant and CHDI Foundation,
Inc. Portions of this exhibit have been omitted and separately filed with the SECwith a
request for confidential treatment. (3)
10.36
Amended and Restated License and CollaborationAgreement among the Registrant, Alnylam
Pharmaceuticals, Inc. and Regulus Therapeutics LLC dated January 1, 2009. Portions of this
exhibit have been omitted and separately filed with the SECwith a request for confidential
treatment. (4)
10.37
Amendment No. 1 toAmended and Restated LicenseAgreement between the Registrant and
OncoGenex Technologies Inc. dated December 18, 2009. (24)
10.38
Amendment Number One to theAmended and Restated License and Collaboration
Agreement dated June 10, 2010 among the Registrant, AlnylamPharmaceuticals, Inc. and
Regulus Therapeutics Inc. Portions of this exhibit have been omitted and separately filed
with the SECwith a request for confidential treatment. (26)
10.39
SecondAmendment to LoanAgreement dated November 15, 2010 between the Registrant
and RBSAsset Finance, Inc. (22)
10.40
Development, Option and LicenseAgreement between the Registrant and Biogen Idec
International Holding Ltd. dated January 3, 2012. Portions of this exhibit have been omitted
and separately filed with the SECwith a request for confidential treatment. (31)
10.41
ThirdAmendment to LoanAgreement dated June 24, 2012 between the Registrant and RBS
Asset Finance, Inc. (32)
10.42
DMPKResearch, Development, Option and LicenseAgreement between the Registrant and
Biogen IdecMA Inc. dated June 27, 2012. Portions of this exhibit have been omitted and
separately filed with the SECwith a request for confidential treatment. (32)
10.43
Letter Agreement Amendment between the Registrant andAlnylamPharmaceuticals, Inc.
datedAugust 27, 2012. Portions of this exhibit have been omitted and separately filed with
the SECwith a request for confidential treatment. (33)
10.44
Amendment #2 to Research, Development and LicenseAgreement between the Registrant
and Glaxo Group Limited dated October 30, 2012. Portions of this exhibit have been omitted
and separately filed with the SECwith a request for confidential treatment. (37)
10.45
Collaboration, License and Development Agreement between the Registrant andAstraZeneca
AB dated December 7, 2012. Portions of this exhibit have been omitted and separately filed
with the SECwith a request for confidential treatment. (37)
130
